-
Product Insights
Polycythemia Vera – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycythemia Vera - Drugs In Development, 2023’, provides an overview of the Polycythemia Vera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: Otsuka Holdings Co Ltd’s (Deudextromethorphan hydrobromide + Quinidine sulfate)
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Otsuka Holdings Co Ltd's (Deudextromethorphan hydrobromide + Quinidine sulfate) Drug Details: AVP-786 is under development for the treatment of agitation associated with dementia of...
-
Product Insights
NewNet Present Value Model: Protagonist Therapeutics Inc’s PN-235
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's PN-235 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.Drug Operating Profit Model
-
Product Insights
Net Present Value Model: Protagonist Therapeutics Inc’s Rusfertide acetate
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's Rusfertide acetate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rusfertide Acetate in Hemochromatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rusfertide Acetate in Hemochromatosis Drug Details: PTG-300 is under development for the treatment of iron...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AND-019 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AND-019 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug Details:AND-019...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNS-101 in Friedreich Ataxia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNS-101 in Friedreich Ataxia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JNS-101 in Friedreich AtaxiaDrug Details:JNS-101 is under development for the treatment of Friedreich’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PTG-100 in Celiac Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PTG-100 in Celiac Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PTG-100 in Celiac DiseaseDrug Details:PTG-100 is under development for the treatment of celiac...
-
Company Insights
Innovation and Patenting activity of Protagonist Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Protagonist Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...